The p53 pathway: positive and negative feedback loops

Surfing the p53 network

Vogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607 · see citing works

Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms

Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765 · see citing works

Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain

Kussie, P. H., Gorina, S., Marechal, V., Elenbaas, B., Moreau, J., Levine, A. J., & Pavletich, N. P. (1996) · Science · doi:10.1126/science.274.5289.948 · Cited by 2,206 · see citing works

p63, a p53 Homolog at 3q27–29, Encodes Multiple Products with Transactivating, Death-Inducing, and Dominant-Negative Activities

Yang, A., Kaghad, M., Wang, Y., Gillett, E. S., Fleming, M. D., Dötsch, V., Andrews, N. C., Caput, D., & McKeon, F. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80275-0 · Cited by 2,086 · see citing works

Monoallelically Expressed Gene Related to p53 at 1p36, a Region Frequently Deleted in Neuroblastoma and Other Human Cancers

Kaghad, M., Bonnet, H., Yang, A., Créancier, L., Biscan, J.-C., Valent, A., Minty, A. J., Chalon, P., Lélias, J.-M., Dumont, X., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80540-1 · Cited by 1,630 · see citing works

Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53

de Oca Luna, R. M., Wagner, D. S., & Lozano, G. (1995) · Nature · doi:10.1038/378203a0 · Cited by 1,420 · cited 1× · see citing works

The complexity of p53 modulation: emerging patterns from divergent signalsPreprint

Giaccia, A. J., & Kastan, M. B. (1998) · Genes & Development · doi:10.1101/gad.12.19.2973 · Cited by 1,303 · see citing works

Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53

Jones, S. N., Roe, A. E., Donehower, L. A., & Bradley, A. (1995) · Nature · doi:10.1038/378206a0 · Cited by 1,280 · cited 1× · see citing works

Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization

Zindy, F., Eischen, C. M., Randle, D. H., Kamijo, T., Cleveland, J. L., Sherr, C. J., & Roussel, M. F. (1998) · Genes & Development · doi:10.1101/gad.12.15.2424 · Cited by 1,245 · see citing works

The alternative product from the human CDKN2A locus, p14ARF, participates in a regulatory feedback loop with p53 and MDM2

Stott, F. J., Bates, S., James, M. C., McConnell, B. B., Starborg, M., Brookes, S., Palmero, I., Ryan, K. M., Hara, E., Vousden, K. H., et al. (1998) · The EMBO Journal · doi:10.1093/emboj/17.17.5001 · Cited by 1,165 · see citing works

Post‐translational modifications and activation of p53 by genotoxic stresses

Appella, E., & Anderson, C. W. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02225.x · Cited by 1,071 · see citing works

Decision making by p53: life, death and cancer

Oren, M. (2003) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401183 · Cited by 1,063 · see citing works

Dynamics of the p53-Mdm2 feedback loop in individual cells

Lahav, G., Rosenfeld, N., Sigal, A., Geva‐Zatorsky, N., Levine, A. J., Elowitz, M. B., & Alon, U. (2004) · Nature Genetics · doi:10.1038/ng1293 · Cited by 1,015 · see citing works

p73 is a human p53-related protein that can induce apoptosis

Jost, C. A., Marin, M. C., & Jr, W. G. K. (1997) · Nature · doi:10.1038/38298 · Cited by 948 · see citing works

p14ARF links the tumour suppressors RB and p53

Bates, S., Phillips, A. C., Clark, P. A., Stott, F., Peters, G., Ludwig, R. L., & Vousden, K. H. (1998) · Nature · doi:10.1038/25867 · Cited by 918 · see citing works

Gain of function mutations in p53

Dittmer, D., Pati, S., Zambetti, G., Chu, S., Teresky, A. K., Moore, M., Finlay, C., & Levine, A. J. (1993) · Nature Genetics · doi:10.1038/ng0593-42 · Cited by 894 · see citing works

p53 and E2F-1 cooperate to mediate apoptosis.

Wu, X., & Levine, A. J. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3602 · Cited by 836 · see citing works

Cell Surface Trafficking of Fas: A Rapid Mechanism of p53-Mediated Apoptosis

Bennett, M. R., Macdonald, K., Chan, S., Luzio, J. P., Simari, R. D., & Weissberg, P. L. (1998) · Science · doi:10.1126/science.282.5387.290 · Cited by 755 · see citing works

Association of p19ARF with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53

Honda, R., & Yasuda, H. (1999) · The EMBO Journal · doi:10.1093/emboj/18.1.22 · Cited by 724 · see citing works

Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation

Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., Hakem, R., & Benchimol, S. (2003) · Cell · doi:10.1016/s0092-8674(03)00193-4 · Cited by 717 · see citing works

The ubiquitin ligase COP1 is a critical negative regulator of p53

Dornan, D., Wertz, I. E., Shimizu, H., Arnott, D. P., Frantz, G. D., Dowd, P., Rourke, K. O., Koeppen, H., & Dixit, V. M. (2004) · Nature · doi:10.1038/nature02514 · Cited by 700 · see citing works

Tumor suppression by Ink4a-Arf: progress and puzzles.

Lowe, S. W., & Sherr, C. J. (2003) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00013-8 · Cited by 699 · cited 2× · see citing works

Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein.Preprint

Lin, J., Chen, J., Elenbaas, B., & Levine, A. J. (1994) · Genes & Development · doi:10.1101/gad.8.10.1235 · Cited by 652 · see citing works

Regulation of HDM2 activity by the ribosomal protein L11

Lohrum, M. A. E., Ludwig, R. L., Kubbutat, M. H. G., Hanlon, M., & Vousden, K. H. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00134-x · Cited by 626 · see citing works

p19ARF links the tumour suppressor p53 to Ras

Palmero, I., Pantoja, C., & Serrano, M. (1998) · Nature · doi:10.1038/25870 · Cited by 617 · see citing works

E1A signaling to p53 involves the p19ARFtumor suppressorPreprint

de Stanchina, E., McCurrach, M. E., Zindy, F., Shieh, S.-Y., Ferbeyre, G., Samuelson, A. V., Prives, C. L., Roussel, M. F., Sherr, C. J., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.15.2434 · Cited by 607 · see citing works

Interaction between the retinoblastoma protein and the oncoprotein MDM2

Xiao, Z.-X., Chen, J., Levine, A. J., Modjtahedi, N., Xing, J. W., Sellers, W. R., & Livingston, D. M. (1995) · Nature · doi:10.1038/375694a0 · Cited by 586 · see citing works

Generation of oscillations by the p53-Mdm2 feedback loop: A theoretical and experimental study

Bar‐Or, R. L., Maya, R. B.-Y., Segel, L. A., Alon, U., Levine, A. J., & Oren, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.210171597 · Cited by 579 · see citing works

The role of p53 in determining sensitivity to radiotherapy

Gudkov, A. V., & Komarova, E. A. (2003) · Nature reviews. Cancer · doi:10.1038/nrc992 · Cited by 569 · see citing works

p53 Induces Apoptosis by Caspase Activation through Mitochondrial Cytochrome c Release

Schüler, M., Bossy‐Wetzel, E., Goldstein, J. C., Fitzgerald, P., & Green, D. R. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.10.7337 · Cited by 558 · see citing works

Ribosomal Protein L11 Negatively Regulates Oncoprotein MDM2 and Mediates a p53-Dependent Ribosomal-Stress Checkpoint Pathway

Zhang, Y., Wolf, G. W., Bhat, K., Jin, A., Allio, T., Burkhart, W., & Xiong, Y. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.23.8902-8912.2003 · Cited by 556 · see citing works

Inhibition of MDM2-mediated p53 Ubiquitination and Degradation by Ribosomal Protein L5

Dai, M., & Lu, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m403722200 · Cited by 536 · see citing works

A common polymorphism acts as an intragenic modifier of mutant p53 behaviour

Marín, M. C., Jost, C. A., Brooks, L. A., Irwin, M. S., O’Nions, J., TIDY, J. A., James, N. D., McGregor, J., Harwood, C. A., Yuluğ, I. G., et al. (2000) · Nature Genetics · doi:10.1038/75586 · Cited by 511 · see citing works

Ribosomal Protein L23 Activates p53 by Inhibiting MDM2 Function in Response to Ribosomal Perturbation but Not to Translation Inhibition

Dai, M., Zeng, S. X., Jin, Y., Sun, X., David, L. L., & Lu, H. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.17.7654-7668.2004 · Cited by 495 · see citing works

Radiation-induced bystander effects — implications for cancer

Seymour, C. B., & Mothersill, C. E. (2004) · Nature reviews. Cancer · doi:10.1038/nrc1277 · Cited by 478 · see citing works

DNA damage checkpoint control in cells exposed to ionizing radiation

Iliakis, G. E., Wang, Y., Guan, J., & Wang, H. (2003) · Oncogene · doi:10.1038/sj.onc.1206682 · Cited by 474 · see citing works

Cross-talk between Akt, p53 and Mdm2: possible implications for the regulation of apoptosis

Gottlieb, T. M., Martínez-Leal, J. F., Seger, R., Taya, Y., & Oren, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205181 · Cited by 473 · see citing works

A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain

Gaiddon, C., Lokshin, M., Ahn, J., Zhang, T., & Prives, C. (2001) · Molecular and Cellular Biology · doi:10.1128/mcb.21.5.1874-1887.2001 · Cited by 464 · see citing works

Cyclin G is a transcriptional target of the p53 tumor suppressor protein.

Okamoto, K., & Beach, D. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06807.x · Cited by 455 · see citing works

p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

Bergamaschi, D., Gasco, M., Hiller, L., Sullivan, A., Syed, N., Trigiante, G., Yuluğ, I. G., Merlano, M. C., Numico, G., Comino, A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00079-5 · Cited by 445 · see citing works

Mutant p53 gain of function: differential effects of different p53 mutants on resistance of cultured cells to chemotherapy

Blandino, G., Levine, A. J., & Oren, M. (1999) · Oncogene · doi:10.1038/sj.onc.1202314 · Cited by 439 · see citing works

Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy

Bullock, A. N., Henckel, J., & Fersht, A. R. (2000) · Oncogene · doi:10.1038/sj.onc.1203434 · Cited by 435 · see citing works

p53‐inducible Wip1 phosphatase mediates a negative feedback regulation of p38 MAPK‐p53 signaling in response to UV radiation

Takekawa, M., Adachi, M., Nakahata, A., Nakayama, I., Itoh, F., Tsukuda, H., Taya, Y., & Imai, K. (2000) · The EMBO Journal · doi:10.1093/emboj/19.23.6517 · Cited by 419 · see citing works

In Vivo Mitochondrial p53 Translocation Triggers a Rapid First Wave of Cell Death in Response to DNA Damage That Can Precede p53 Target Gene Activation

Erster, S. H., Mihara, M., Kim, R. H., Petrenko, O., & Moll, U. M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.15.6728-6741.2004 · Cited by 367 · see citing works

The p65 subunit of NF-kappa B regulates I kappa B by two distinct mechanisms.Preprint

Scott, M. L., Fujita, T., Liou, H., Nolan, G. P., & Baltimore, D. (1993) · Genes & Development · doi:10.1101/gad.7.7a.1266 · Cited by 355 · see citing works

Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53

Grob, T. J., Novak, U., Maisse, C., Barcaroli, D., Lüthi, A. U., Pirnia, F., Hügli, B., Graber, H. U., Laurenzi, V. D., Fey, M. F., et al. (2001) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4400962 · Cited by 340 · see citing works

The Ribosomal L5 Protein Is Associated with mdm-2 and mdm-2-p53 Complexes

Maréchal, V., Elenbaas, B., Piette, J., Nicolas, J. C., & Levine, A. J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.11.7414 · Cited by 318 · see citing works

The p53 functional circuit

Jin, S. V., & Levine, A. J. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.23.4139 · Cited by 310 · see citing works

The common and distinct target genes of the p53 family transcription factors

Harms, K. L., Nozell, S. E., & Chen, X. (2004) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-003-3304-4 · Cited by 296 · see citing works

The p53MH algorithm and its application in detecting p53-responsive genes

Hoh, J., Jin, S. V., Parrado, T., Edington, J., Levine, A. J., & Ott, J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.132268899 · Cited by 295 · see citing works

Nucleolar Arf Tumor Suppressor Inhibits Ribosomal RNA Processing

Sugimoto, M., Kuo, M.-L., Roussel, M. F., & Sherr, C. J. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00057-1 · Cited by 273 · see citing works

Cyclin G Recruits PP2A to Dephosphorylate Mdm2

Okamoto, K., Li, H., Jensen, M. R., Zhang, T., Taya, Y., Thorgeirsson, S. S., & Prives, C. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00504-x · Cited by 215 · see citing works

Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function

de Vries, A., Flores, E. R., Miranda, B., Hsieh, H.-M., van Oostrom, C. T. M., Sage, J., & Jacks, T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052713099 · Cited by 207 · see citing works

Deregulated β‐catenin induces a p53‐ and ARF‐dependent growth arrest and cooperates with Ras in transformation

Damalas, A., Kahan, S., Shtutman, M. S., Ben‐Ze'ev, A., & Oren, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.17.4912 · Cited by 206 · see citing works

Targeting the p53–MDM2 interaction to treat cancer

Klein, C., & Vassilev, L. T. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6602164 · Cited by 204 · see citing works

The presence of p53 mutations in human osteosarcomas correlates with high levels of genomic instability

Overholtzer, M., Rao, P. H., Favis, R., Lu, X.-Y., Elowitz, M. B., Barany, F., Ladanyi, M., Gorlick, R., & Levine, A. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1934852100 · Cited by 193 · see citing works

Topors Functions as an E3 Ubiquitin Ligase with Specific E2 Enzymes and Ubiquitinates p53

Rajendra, R., Malegaonkar, D., Pungaliya, P., Marshall, H., Rasheed, Z. A., Brownell, J. E., Liu, L. F., Lutzker, S. G., Saleem, A., & Rubin, E. H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.c400300200 · Cited by 192 · see citing works

Regulation of p53 stability and activity in response to genotoxic stress

Colman, M. S., Afshari, C. A., & Barrett, J. C. (2000) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00035-1 · Cited by 181 · see citing works

Isolation of p53‐target genes and their functional analysis

Nakamura, Y. (2004) · Cancer Science · doi:10.1111/j.1349-7006.2004.tb03163.x · Cited by 169 · see citing works

The MDM2 Oncoprotein Binds Specifically to RNA through its RING Finger Domain

Elenbaas, B., Dobbelstein, M., Roth, J. C., Shenk, T. E., & Levine, A. J. (1996) · Molecular Medicine · doi:10.1007/bf03401903 · Cited by 164 · see citing works

Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery

Kimura, S. H., Ikawa, M., Ito, A., Okabe, M., & Nojima, H. (2001) · Oncogene · doi:10.1038/sj.onc.1204270 · Cited by 148 · see citing works

Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53

Komarova, E. A., Diatchenko, L. B., Rokhlin, O. W., Hill, J. E., Wang, Z. J., Krivokrysenko, V. I., Feinstein, E., & Gudkov, A. V. (1998) · Oncogene · doi:10.1038/sj.onc.1202303 · Cited by 140 · see citing works

The Promyelocytic Leukemia Protein Protects p53 from Mdm2-mediated Inhibition and Degradation

Louria‐Hayon, I., Grossman, T., Sionov, R. V., Alsheich-Bartok, O., Pandolfi, P. P., & Haupt, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301264200 · Cited by 135 · see citing works

p53 induces the expression of its antagonist p73ΔN, establishing an autoregulatory feedback loop

Kartasheva, N. N., Contente, A., Lenz-Stöppler, C., Roth, J. C., & Dobbelstein, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205584 · Cited by 126 · see citing works

Identification of a Minimal Transforming Domain of p53: Negative Dominance through Abrogation of Sequence-Specific DNA Binding

Shaulian, E., Zauberman, A., Ginsberg, D., et al. (1992) · Molecular and Cellular Biology · doi:10.1128/mcb.12.12.5581-5592.1992 · Cited by 113 · see citing works

Myc-ARF (Alternate Reading Frame) Interaction Inhibits the Functions of Myc

Datta, A., Nag, A., Pan, W., Hay, N., Gartel, A. L., Colamonici, O. R., Mori, Y., & Raychaudhuri, P. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312305200 · Cited by 112 · see citing works

A Genetic Approach to Mapping the p53 Binding Site in the MDM2 Protein

Freedman, D. A., Epstein, C. B., Roth, J. C., & Levine, A. J. (1997) · Molecular Medicine · doi:10.1007/bf03401678 · Cited by 91 · see citing works

Siah-1b is a direct transcriptional target of p53: Identification of the functional p53 responsive element in the siah-1b promoter

Fiucci, G., Beaucourt, S., Duflaut, D., Lespagnol, A., Stumptner-Cuvelette, P., Géant, A., Buchwalter, G., Tuynder, M., Susini, L., Lassalle, J., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400177101 · Cited by 80 · see citing works

Cyclin A-CDK Phosphorylation Regulates MDM2 Protein Interactions

Zhang, T., & Prives, C. L. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011326200 · Cited by 70 · see citing works

Characterization of a Novel Strain of Bacillus thuringiensis

López-Meza, J. E., & Ibarra, J. E. (1996) · Applied and Environmental Microbiology · doi:10.1128/aem.62.4.1306-1310.1996 · Cited by 66 · see citing works

The Werner syndrome protein contributes to induction of p53 by DNA damage

Blander, G., Zalle, N., Martínez-Leal, J. F., Bar‐Or, R. L., Yu, C., & Oren, M. (2000) · The FASEB Journal · doi:10.1096/fj.00-0171fje · Cited by 49 · see citing works

Siah-1L, a novel transcript variant belonging to the human Siah family of proteins, regulates β-catenin activity in a p53-dependent manner

Iwai, A., Marusawa, H., Matsuzawa, S.-I., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1208016 · Cited by 47 · see citing works

p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors

Epstein, C. B., Attiyeh, E. F., Hobson, D. A., et al. (1998) · Oncogene · doi:10.1038/sj.onc.1201734 · Cited by 39 · see citing works

MDM2 and Promyelocytic Leukemia Antagonize Each Other through Their Direct Interaction with p53

Zhu, H., Wu, L., & Maki, C. G. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308302200 · Cited by 30 · see citing works

Inhibition of p53-induced apoptosis without affecting expression of p53-regulated genes

Lotem, J., Gal, H., Kama, R., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1031695100 · Cited by 21 · see citing works

Individual promoter and intron p53‐binding motifs from the rat Cyclin G1 promoter region support transcriptional activation by p53 but do not show co‐operative activation

Yardley, G., Zauberman, A., Oren, M., & Jackson, P. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00650-4 · Cited by 14 · see citing works

Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas

Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · see citing works

Mitochondria: More Than Just a Powerhouse

McBride, H. M., Neuspiel, M., & Wasiak, S. (2006) · Current Biology · doi:10.1016/j.cub.2006.06.054 · Cited by 1,985 · see citing works

Transcriptional control of human p53-regulated genes

Riley, T., Sontag, E., Chen, P., & Levine, A. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2395 · Cited by 1,921 · see citing works

Senescence and aging: Causes, consequences, and therapeutic avenues

McHugh, D., & Gil, J. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201708092 · Cited by 1,233 · see citing works

Census and evaluation of p53 target genes

Fischer, M. (2017) · Oncogene · doi:10.1038/onc.2016.502 · Cited by 971 · see citing works

Targeting transcription factors in cancer — from undruggable to reality

Bushweller, J. H. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0196-7 · Cited by 919 · see citing works

Functional characterization of somatic mutations in cancer using network-based inference of protein activity

Alvarez, M. J., Shen, Y., Giorgi, F. M., Lachmann, A., Ding, B. B., Ye, B. H., & Califano, A. (2016) · Nature Genetics · doi:10.1038/ng.3593 · Cited by 966 · see citing works

An integrated view of oxidative stress in aging: basic mechanisms, functional effects, and pathological considerations

Kregel, K. C., & Zhang, H. J. (2007) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00327.2006 · Cited by 883 · see citing works

Therapy-induced senescence in cancer.

Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq364 · Cited by 824 · see citing works

Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy

Tovar, C., Rosinski, J., Filipovic, Z., Higgins, B., Kolinsky, K., Hilton, H., Zhao, X., Vu, B. T., Qing, W., Packman, K., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507493103 · Cited by 708 · see citing works

The complexity of p53 stabilization and activation

Lavin, M. F., & Gueven, N. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401925 · Cited by 701 · see citing works

The Regulation of AMPK β1, TSC2, and PTEN Expression by p53: Stress, Cell and Tissue Specificity, and the Role of These Gene Products in Modulating the IGF-1-AKT-mTOR Pathways

Feng, Z., Hu, W., de Stanchina, E., Teresky, A. K., Jin, S., Lowe, S., & Levine, A. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4149 · Cited by 633 · see citing works

Discovery of RG7388, a Potent and Selective p53–MDM2 Inhibitor in Clinical Development

Ding, Q., Zhang, Z., Liu, J.-J., Jiang, N., Zhang, J., Ross, T. M., Chu, X.-J., Bartkovitz, D., Podlaski, F., Janson, C., et al. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400487c · Cited by 595 · see citing works

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

Ray-Coquard, I., Blay, J.-Y., Italiano, A., Le Cesne, A., Penel, N., Zhi, J., Heil, F., Rueger, R., Graves, B., Ding, M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70474-6 · Cited by 571 · see citing works

MDM2 inhibitors for cancer therapy

Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532 · see citing works

Interlinked Fast and Slow Positive Feedback Loops Drive Reliable Cell Decisions

Brandman, O., Ferrell, J. E., Li, R., & Meyer, T. (2005) · Science · doi:10.1126/science.1113834 · Cited by 466 · see citing works

Delayed ageing through damage protection by the Arf/p53 pathway

Matheu, A., Maraver, A., Klatt, P., Flores, I., Garcia-Cao, I., Borras, C., Flores, J. M., Viña, J., Blasco, M. A., & Serrano, M. (2007) · Nature · doi:10.1038/nature05949 · Cited by 466 · see citing works

The p53 Pathway in Glioblastoma

Zhang, Y., Dube, C., Gibert, M., Cruickshanks, N., Wang, B., Coughlan, M., Yang, Y., Setiady, I., Deveau, C., Saoud, K., et al. (2018) · Cancers · doi:10.3390/cancers10090297 · Cited by 440 · see citing works

Recurrent Initiation: A Mechanism for Triggering p53 Pulses in Response to DNA Damage

Batchelor, E., Mock, C. S., Bhan, I., Loewer, A., & Lahav, G. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.016 · Cited by 422 · see citing works

Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development

Vu, B., Wovkulich, P., Pizzolato, G., Lovey, A., Ding, Q., Jiang, N., Liu, J.-J., Zhao, C., Glenn, K., Wen, Y., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml4000657 · Cited by 395 · see citing works

Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy

Yue, X., Zhao, Y., Xu, Y., Zheng, M., Feng, Z., & Hu, W. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.03.030 · Cited by 308 · see citing works

Coordination and communication between the p53 and IGF-1–AKT–TOR signal transduction pathways

Levine, A. J., Feng, Z., Mak, T. W., You, H., & Jin, S. (2006) · Genes & Development · doi:10.1101/gad.1363206 · Cited by 321 · see citing works

MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models

Tovar, C., Graves, B., Packman, K., Filipovic, Z., Xia, B. H. M., Tardell, C., Garrido, R., Lee, E., Kolinsky, K., To, K.-H., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2807 · Cited by 283 · see citing works

Functional Human Telomeres Are Recognized as DNA Damage in G2 of the Cell Cycle

Verdun, R. E., Crabbe, L., Haggblom, C., & Karlseder, J. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.09.024 · Cited by 284 · see citing works

Cell fate decision mediated by p53 pulses

Zhang, X.-P., Liu, F., Cheng, Z., & Wang, W. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813088106 · Cited by 253 · see citing works

Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization

Graves, B., Thompson, T., Xia, M., Janson, C., Lukacs, C., Deo, D., Di Lello, P., Fry, D., Garvie, C., Huang, K.-S., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203789109 · Cited by 230 · see citing works

The c‐myc Promoter: Still MysterY and Challenge

(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(07)99004-1 · Cited by 211 · see citing works

Keratinocyte growth factor (KGF) enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells

Rossi, S. W., Jeker, L. T., Ueno, T., Kuse, S., Keller, M. P., Zuklys, S., Gudkov, A. V., Takahama, Y., Krenger, W., Blazar, B. R., et al. (2007) · Blood · doi:10.1182/blood-2006-10-049767 · Cited by 215 · see citing works

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors

Holzer, P., Masuya, K., Furet, P., Kallen, J., Valat-Stachyra, T., Ferretti, S., Berghausen, J., Bouisset-Leonard, M., Buschmann, N., Pissot-Soldermann, C., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00810 · Cited by 203 · see citing works

The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity

Poyurovsky, M. V., Priest, C., Kentsis, A., Borden, K. L., Pan, Z., Pavletich, N., & Prives, C. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601465 · Cited by 203 · see citing works

miR-605 joins p53 network to form a p53:miR-605:Mdm2 positive feedback loop in response to stress

Xiao, J., Lin, H., Luo, X., Luo, X., & Wang, Z. (2011) · The EMBO Journal · doi:10.1038/emboj.2010.347 · Cited by 189 · see citing works

The TP53 website: An integrative resource centre for the TP53 mutation database and TP53 mutant analysis

Leroy, B., Fournier, J. L., Ishioka, C., Monti, P., Inga, A., Fronza, G., & Soussi, T. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1033 · Cited by 185 · see citing works

Early aging–associated phenotypes in Bub3/Rae1 haploinsufficient mice

Baker, D. J., Jeganathan, K. B., Malureanu, L., Perez-Terzic, C., Terzic, A., & van Deursen, J. M. A. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200507081 · Cited by 175 · see citing works

ATM activates p53 by regulating MDM2 oligomerization and E3 processivity

Cheng, Q., Chen, L., Li, Z., Lane, W. S., & Chen, J. (2009) · The EMBO Journal · doi:10.1038/emboj.2009.294 · Cited by 165 · see citing works

Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme

England, B., Huang, T., & Karsy, M. (2013) · Tumor Biology · doi:10.1007/s13277-013-0871-3 · Cited by 163 · see citing works

The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents

Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152 · see citing works

Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3

LeBron, C., Chen, L., Gilkes, D. M., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601032 · Cited by 122 · see citing works

Distinct mechanisms act in concert to mediate cell cycle arrest

Toettcher, J. E., Loewer, A., Ostheimer, G. J., Yaffe, M. B., Tidor, B., & Lahav, G. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806196106 · Cited by 112 · see citing works

Current status and new treatment approaches in TP53 mutated AML

Hunter, A. M., & Sallman, D. A. (2019) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2019.05.004 · Cited by 102 · see citing works

Integrating genetic and gene expression evidence into genome-wide association analysis of gene sets

Xiong, Q., Ancona, N., Hauser, E. R., Mukherjee, S., & Furey, T. S. (2012) · Genome Research · doi:10.1101/gr.124370.111 · Cited by 103 · see citing works

Small-molecule MDM2/X inhibitors and PROTAC degraders for cancer therapy: advances and perspectives

Fang, Y., Liao, G., & Yu, B. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.003 · Cited by 106 · see citing works

Differential Roles of ATM- and Chk2-Mediated Phosphorylations of Hdmx in Response to DNA Damage

Pereg, Y., Lam, S., Teunisse, A., Biton, S., Meulmeester, E., Mittelman, L., Buscemi, G., Okamoto, K., Taya, Y., Shiloh, Y., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00562-06 · Cited by 93 · see citing works

Mitochondrial recoupling: a novel therapeutic strategy for cancer

Baffy, G., Derdak, Z., & Robson, S. C. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.245 · Cited by 88 · see citing works

A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

Jeay, S., Gaulis, S., Ferretti, S., Bitter, H., Ito, M., Valat, T., Murakami, M., Ruetz, S., Guthy, D. A., Rynn, C., et al. (2015) · eLife · doi:10.7554/elife.06498 · Cited by 85 · see citing works

NFκB/p53 crosstalk—a promising new therapeutic target

Schneider, G., & Krämer, O. H. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.10.003 · Cited by 87 · see citing works

Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

Jeay, S., Ferretti, S., Holzer, P., Fuchs, J., Chapeau, E. A., Wartmann, M., Sterker, D., Romanet, V., Murakami, M., Kerr, G., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0338 · Cited by 87 · see citing works

Translational approaches targeting the p53 pathway for anti‐cancer therapy

Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77 · see citing works

Tumor Suppressor Protein Pdcd4 Inhibits Translation of p53 mRNA

Wedeken, L., Singh, P., & Klempnauer, K.-H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.269456 · Cited by 75 · see citing works

Extensive Post-translational Modification of Active and Inactivated Forms of Endogenous p53

DeHart, C. J., Chahal, J. S., Flint, S. J., & Perlman, D. H. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.030254 · Cited by 70 · see citing works

p21 does not protect cancer cells from apoptosis induced by nongenotoxic p53 activation

Xia, M., Knezevic, D., & Vassilev, L. T. (2011) · Oncogene · doi:10.1038/onc.2010.413 · Cited by 64 · see citing works

The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy

Liao, G., Yang, D., Ma, L., Li, W., Hu, L., Zeng, L., Wu, P., Duan, L., & Liu, Z. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.044 · Cited by 63 · see citing works

Discovery of potent and selective spiroindolinone MDM2 inhibitor, RO8994, for cancer therapy

Zhang, Z., Ding, Q., Liu, J.-J., Zhang, J., Jiang, N., Chu, X.-J., Bartkovitz, D., Luk, K.-C., Janson, C., Tovar, C., et al. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.05.072 · Cited by 60 · see citing works

In Vitro Three‐Dimensional Liver Models for Nanomaterial DNA Damage Assessment

Llewellyn, S. V., Niemeijer, M., Nymark, P., Moné, M. J., van de Water, B., Conway, G. E., Jenkins, G. J. S., & Doak, S. H. (2021) · Small · doi:10.1002/smll.202006055 · Cited by 41 · see citing works

Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells

Moran, D. M., & Maki, C. G. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1220 · Cited by 35 · see citing works

Modification of Drosophila p53 by SUMO Modulates Its Transactivation and Pro-apoptotic Functions

Mauri, F., McNamee, L. M., Lunardi, A., Chiacchiera, F., Del Sal, G., Brodsky, M. H., & Collavin, L. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710186200 · Cited by 33 · see citing works

Hdm2 Nuclear Export, Regulated by Insulin-like Growth Factor-I/MAPK/p90Rsk Signaling, Mediates the Transformation of Human Cells

Jackson, M. W., Patt, L. E., LaRusch, G. A., Donner, D. B., Stark, G. R., & Mayo, L. D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511617200 · Cited by 29 · see citing works

Early onset senescence occurs when fibroblasts lack the glutamate–cysteine ligase modifier subunit

Chen, Y., Johansson, E., Fan, Y., Shertzer, H. G., Vasiliou, V., Nebert, D. W., & Dalton, T. P. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.05.003 · Cited by 28 · see citing works

The phenotype of MDM2 auto-degradation after DNA damage is due to epitope masking by phosphorylation

Cheng, Q., & Chen, J. (2011) · Cell Cycle · doi:10.4161/cc.10.7.15249 · Cited by 21 · see citing works

The tumor suppressor phosphatase PP2A-B56α regulates stemness and promotes the initiation of malignancies in a novel murine model

Janghorban, M., Langer, E. M., Wang, X., Zachman, D., Daniel, C. J., Hooper, J., Fleming, W. H., Agarwal, A., & Sears, R. C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188910 · Cited by 19 · see citing works

Susceptibility to metanephric apoptosis in bradykinin B2 receptor null mice via the p53-Bax pathway

Fan, H., Stefkova, J., & El-Dahr, S. S. (2006) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00037.2006 · Cited by 13 · see citing works

Low doses of niclosamide and quinacrine combination yields synergistic effect in melanoma via activating autophagy-mediated p53-dependent apoptosis

Zheng, X., Zhang, J., Li, S., Gao, X., Zhang, Y., Wang, M., Dong, L., Sun, L., Zhao, N., Ma, Z., et al. (2022) · Translational Oncology · doi:10.1016/j.tranon.2022.101425 · Cited by 12 · see citing works

Acute loss of DP1, but not DP2, induces <i>p53</i> mRNA and augments p21Waf1/Cip1 and senescence

Ohdaira, H., Sekiguchi, M., Miyata, K., Sasaki, T., & Yoshida, K. (2012) · Cell Biochemistry and Function · doi:10.1002/cbf.1818 · Cited by 5 · see citing works

Cyclin E-CDK2 is a regulator of p27Kip1.Preprint

Sheaff, R. J., Groudine, M. T., Gordon, M., Roberts, J., & Clurman, B. E. (1997) · Genes & Development · doi:10.1101/gad.11.11.1464 · Cited by 910 · see citing works

Cyclin specificity: how many wheels do you need on a unicycle?

Miller, M. E., & Cross, F. R. (2001) · Journal of Cell Science · doi:10.1242/jcs.114.10.1811 · Cited by 106 · see citing works

Cyclin-Binding Motifs Are Essential for the Function of p21 <i> ^CIP1 </i>

Chen, J., Saha, P., Kornbluth, S., Dynlacht, B. D., & Dutta, A. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.9.4673 · Cited by 320 · see citing works

p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F.Preprint

Zhu, L., Harlow, E. E., & Dynlacht, B. D. (1995) · Genes & Development · doi:10.1101/gad.9.14.1740 · Cited by 252 · see citing works

Cyclins and CDKS in development and cancer: lessons from genetically modified mice

Santamarı́a, D. (2006) · Frontiers in bioscience · doi:10.2741/1871 · Cited by 164 · see citing works